Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

r-related death in men and women in the U.S., with 160,000 deaths estimated in 2007. Approximately 80 to 85 percent of these patients will be diagnosed with NSCLC, with the majority being diagnosed with locally advanced or metastatic disease.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on obj
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/1/2015)... DUBLIN , June 24, 2015 ... has announced the addition of the "Future ... Banking Market 2015: Supplier Shares and Country Forecasts" ... Horizons and Growth Strategies in the European Blood ... prepared in order to help current suppliers and ...
(Date:7/1/2015)... -- Celsion Corporation (NASDAQ: CLSN ), an oncology drug ... , Chairman, President and CEO, is scheduled to present ... July 8, 2015, at 4:15 p.m. Eastern Time. The conference ... at 119 W. 56th Street, New York ... the presentation will be available in the Events & ...
(Date:7/1/2015)... 2015   Continental Clinical Solutions (Continental) announced it is expanding its ... increased volume in clinical studies and demand for unique patient populations.  ... ... ... ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4
... Sept. 23, 2011 Henry Ford Hospital became the third ... Stimulation (DBS) procedure inside an Intraoperative Magnetic Resonance Imaging scanner, ... the neurosurgical toolbox," says Jason M. Schwalb, M.D., Director of ... "Although awake surgery with brain mapping is still ...
... Science, Inc., creators of the Basis™ B1 band, today announced ... and gaming luminaries including Kevin Colleran, Charles and Kai Huang, ... Chris Verplaetse to join the company,s executive team as vice ... launched later this year, the Basis B1 band is the ...
Cached Medicine Technology:DBS Operation for Parkinson's Disease Performed Inside iMRI 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 3
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. ... newly released white paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the ... is available at: http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting Partnership put ... ten list they hope will guide future mesothelioma research. Surviving Mesothelioma has just ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Citizens ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... ML-T balance line. With larger-than-average weighing pans, ML-T balances give operators the room ... in-class footprint, this extra real estate makes ML-T balances a perfect choice for ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Thule Atmos X4 offers protection with ... ensure it lived up to Thule’s rigorous standards. Due to its Bi-ComponentArmor and ShockStop ... owners have come to expect. , The Thule Atmos X4 has also ...
Breaking Medicine News(10 mins):Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:METTLER TOLEDO Launches Compact ML-T Balances: Larger Pan Offers Greater Weighing Flexibility in Tight Spaces 2
... might spur obesity, German study finds , FRIDAY, Aug. 7 ... financial debt, German researchers suggest. , In their study, Eva ... the weight of more than 9,000 people. , They found ... debt were classified as obese, a full quarter of those ...
... , , CENTENNIAL, Colo., Aug. 7 ... and soft tissue allografts for use in surgical procedures, announced today that ... in the Healthcare category of the Top Company awards program hosted by ... is hosting the business awards program for the 22nd consecutive year. ...
... , , , ... WCRX ) today announced its results for the quarter ... 2009 increased 7.1% to $250.8 million over the prior year quarter. ... sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which were ...
... ... onsite employee health services and technology solutions, today announced the opening of a Chicago field ... region. , ... August 7, 2009 -- Marathon Health, a leading provider of onsite employee health services ...
... and most expensive patients need fewer health care resources and ... nurse-physician primary care team that tracks their health and offers ... Johns Hopkins Bloomberg School of Public Health. The research, published ... that in the first eight months of a randomized controlled ...
... rate of heart attack, tripled rate of death seen ... New research shows that men diagnosed with the chest ... neither artery-opening angioplasty nor coronary-bypass surgery reduced long-term mortality ... newly diagnosed with angina at 40 primary-care practices in ...
Cached Medicine News:Health News:Slide Into Debt Could Bring Wider Waistline 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Marathon Health Expands Midwest Presence 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:Men With Angina Do Worse Than Women 2Health News:Men With Angina Do Worse Than Women 3
... the quantitative determination of alanine ... plasma. Liquid buffer and dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Medicine Products: